Acorn Capital Advisors’s Bicara Therapeutics BCAX Stock Holding History
Bought
Maintained
Sold
Other funds holding BCAX
SL
Acorn Capital Advisors's BCAX Position: Q3 2026 in Review
Acorn Capital Advisors increased its Bicara Therapeutics (BCAX) stake by 3.9% in Q3 2026, buying an estimated $626K and bringing the position to 668,381 shares worth $12.4M. The position accounts for 3.42% of the portfolio, ranked #8.
Acorn Capital Advisors first reported a position in BCAX in Q4 2024 and has held it in 8 quarters since. The position peaked at $19.1M in Q2 2026. 169 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.
- Acorn Capital Advisors held 668,381 shares of Bicara Therapeutics worth $12.4M as of Q3 2026.
- Acorn Capital Advisors bought 25,000 Bicara Therapeutics shares in Q3 2026, an estimated $626K.
- Bicara Therapeutics made up 3.42% of Acorn Capital Advisors's portfolio in Q3 2026, its #8 holding.
- Acorn Capital Advisors first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 8 quarters since.
- Acorn Capital Advisors's Bicara Therapeutics position peaked at $19.1M in Q2 2026.
- 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.
Based on Acorn Capital Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.